Full Text Here

Funding is open to academic and industry researchers through the Foundation’s Pipeline Programs, which consist of three annually recurring initiatives, known collectively as The Edmond J. Safra Core Programs for PD Research, as well as the industry-exclusive Therapeutics Development Initiative. The Foundation seeks investigator-initiated proposals focused on the following critical points along the translational pathway to new therapies for Parkinson’s disease:

• Testing Novel Hypotheses: Quick support for high-risk, high-reward projects with little to no existing preliminary data, but potential to significantly impact our understanding or treatment of PD.
• Validating Novel Targets: Support for work demonstrating whether modulation of a novel biological target has impact in a PD-relevant pre-clinical model — an essential step to the development of potential targeted therapies.
• Catalyzing and Expanding Preclinical Development: Industry-exclusive support for preclinical development of Parkinson’s disease therapies with potential to fundamentally alter disease course and/or improve treatment of symptoms above and beyond current standards of care.
• Clinically Testing Novel Therapies: Support for clinical testing of promising PD therapies that may significantly and fundamentally improve treatment of PD.

“The Pipeline Programs are a core element of our Foundation’s efforts to drive research that will speed therapeutic development at historically under-funded points on the pipeline,” said Todd Sherer, the Foundation’s acting CEO. “The programs are part of MJFF’s progressive work to keep the most promising and significant projects moving forward toward notably improving quality of life for patients now and in the future.”

Brief program descriptions follow. Full details are available at www.michaeljfox.org/research.

For Business Planning Services Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

Published by Rodman and Renshaw and EpstineBeckerGreen full Text Here

Based on interviews with over 75 healthcare investors in the US, this report offers valuable insight into emerging trends in investment activity, as well as a detailed forecast for specific subsectors, including biotechnology and pharmaceuticals; medical devices; healthcare providers and payors; and healthcare services.

Respondents to this survey unanimously agree that healthcare M&A activity will either increase or remain at its current level over the next 12 months. The biotechnology and pharmaceuticals subsector and the healthcare services subsector are particularly likely to witness a significant increase in M&A during this time, according to 87% and 83% of respondents, respectively.

Investment patterns are likely to vary according to industry over the next 12 months. Strategic buyers are likely to be most active in the biotechnology and pharmaceuticals subsector, following on a recent wave of large-cap deals including the US$68bn Pfizer-Wyeth merger and the US$44bn Roche-Genentech merger. Financial buyers, on the other hand, are likely to focus their attention on the healthcare services space, where recent private equity buyouts include TPG Capital’s US$5.3bn acquisition of IMS Health.

Click Here for Business Planning Services

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

This guidance provides information on the implementation of section 1102 of the Food and Drug Administration Amendments Act of 2007 (FDAAA), which adds new section 524 to the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. 360n). Section 524 authorizes FDA to award priority review vouchers to sponsors of certain tropical disease product applications that meet the criteria specified by the Act. A priority review voucher may be used by the sponsor who obtains it or another sponsor to obtain a priority review for a different application. A priority review voucher may be transferred from the sponsor who obtains it to another sponsor.

These vouchers are valued at between US$50 and US$300 million, and there is grant money available to fund development it is a great way of generating large anounts of value whilst saving lives.

For Business Planning Services Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

Free Strategy Consultation - Biotech Pharma Regualtory

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

A new Fund launched today by Oxford University will enable donors to support proof of concept and prototyping work to turn more research ideas into commercially-viable technologies, products and services.

The Oxford Invention Fund, which will be managed by Oxford University’s technology transfer company Isis Innovation, is part of Oxford Thinking, the Campaign to raise a minimum of £1.25bn for the collegiate University.

It is widely recognised that there is an ‘innovation gap’ between the early stages of an invention or idea and the point when it is mature enough to be commercialised through a license or spin-out company. The new initiative aims to raise up to £5m to create a self-sustaining fund to help develop Oxford inventions to the point when they can attract commercial investment.

‘Many university-based inventions lack well-developed product prototypes and vital experimental data to help them succeed, and obtaining funds for such work from venture capital providers or research funders is still a problem,’ said Tom Hockaday, Managing Director of Isis Innovation. ‘The aim of this Fund is to support the work needed to make even more Oxford inventions attractive propositions for licensing or investment.’

‘The Oxford Invention Fund provides the opportunity for donors to the University to see their donations used to support innovation and enterprise in Oxford, and to see a return to the University from successful new business ventures,’ said Bernard Taylor, Chairman of Isis Innovation.

Isis Innovation has a long track-record of success in exploiting research discoveries and ideas from Oxford University. In the last ten years Isis has set up 54 new technology spin-out companies, over 90% of which are still in business, and concluded 500 technology licensing transactions. Isis currently manages over 750 technology projects and files on average more than one new patent application each week.

Isis Innovation has managed the highly successful Oxford University Challenge Seed Fund (UCSF) which, since it was first launched in 1999, has awarded £5.7m, financing 102 projects and prompting the formation of 31 spin-out companies and the completion of 51 commercial deals.

The Oxford Invention Fund is modelled after the UCSF, with returns from its investments re-invested in further projects so that it can continue to support innovation at Oxford for many years to come. It is hoped that one day money generated from the Fund could be used to subsidise scholarships and bursaries to help the next generation of inventors and scientists.

For Business Planning and Fund Raising Services Click Here

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

Free Strategy Consultation - Biotech Pharma Regualtory

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

Plans have been announced to establish a growth fund worth £1 billion to support business and economic development in those English regions likely to be hit by public spending cuts.

The fund is due to operate as from next year until 2013 in an effort to smooth the transition to private-sector led growth.

It will play a part in replacing the nine English Regional Development Agencies which are to be phased out by March 2012. A number of RDA roles will be transferred to smaller local enterprise partnerships.

Making the announcement, Nick Clegg, the Deputy Prime Minister, said: “While we sort out the nation’s finances we can also help to foster a thriving and more balanced economy so that no region or community gets left behind.

“The Regional Growth Fund will create the conditions for growth and enterprise in the regions by stimulating investment and create sustainable private sector jobs.

In a joint letter sent to councils and business leaders, Business Secretary, Vince Cable and Communities Secretary, Eric Pickles have asked them to consider forming new local enterprise partnerships that can provide strategic leadership in their local areas and create the right environment for business success.

Vince Cable said: “We are determined to rebalance the economy towards the private sector, so it’s important we create a more effective structure to drive economic growth and development across the country.

“We want a structure that reflects the genuine interests and commitment of enterprise, local councils and other stakeholders like universities and colleges. Local enterprise partnerships will provide that vision and then take on the task of renewing local economies and tackling local barriers to growth.”

Local enterprise partnerships will tackle issues including planning and housing, local transport and infrastructure, employment, enterprise and supporting business start-ups.

The statement, however, made clear that some roles currently carried out by the RDAs will be switched to Whitehall, such as inward investment, sector leadership, business support, innovation and access to finance.

Further details of the Regional Growth Fund, and the creation of LEPs, will be set out in the forthcoming White Paper on local and regional growth.

Responding to the announcement, David Frost, the director general of the British Chambers of Commerce (BCC), said: “Whatever new structures emerge, it is clear that local business leaders need to play a central role in defining every area’s economic future.

“Given the long-standing economic challenges that face so many parts of the country, business must be assured that private sector growth, job creation, and balanced local economies are LEPs’ overriding priorities.”

But Mr Frost warned: “While business will wait to see detailed plans on the proposed Regional Growth Fund, what’s clear from the outset is that the Fund will have significantly less resources to support business growth than previous arrangements.

“While business has been fully supportive of the government’s drive to reduce the UK’s deficit, we believe that investment in the business environment must remain a key priority – especially in those areas of the country that have not seen significant private-sector growth.”

Click Here for Business Planning Services

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

Free Strategy Consultation - Biotech Pharma Regualtory

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

Site Here

The BIA Fundmap provides easy navigation to the grants and funding available to businesses in the UK bioscience sector.

Click Here for Drug Development Services

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

Free Strategy Consultation - Biotech Pharma Regualtory

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

Short Term Project Funding is designed to support small research projects to explore the feasibility of innovative new products and processes.

In the first stage, funds of up to £3,000 are available to support collaborative projects between industry and METRC’s academic members.

Second stage funds of £7,000 are available for the most successful projects providing there is a match from the industrial partner.

For more information please go to our website www.molecularengineering.co.uk/funding_calls.php

If you would like to discuss a project idea please contact one of the METRC team:

METRC@sheffield.ac.uk

+44 (0)114 222 9450

About METRC

METRC is a virtual lab pooling expertise from leading research centres at Universities across the

North of England. Our focus is on soft nanotechnology and its applications in industry. Our target

markets include home and personal care, medicine and healthcare, and energy.

CMC Consulting Services

Damien Bové is THE Drug Development and Regulatory Consultant (pharmaceutical or biotechnology), I work with my clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free!

Sign up for the most value add free newsource you can get for free. We spend a huge amount of time and effort monitoring the main drug / device regulators websites for changes in the regulatory environment, and capture between 20 and 40 new regulations, rules and initiatives each month, and summaries them in a fantastic FREE monthly Regulatory and Market Round Up. You can Un-Subscribe at any time and we don not share your details with anybody. You can’t afford to miss out on this service. Just fill in the form below.

First name

Phone #1

E-mail address

Free Strategy Consultation - Biotech Pharma Regualtory

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

Taken From RMS Bentley Jennison Pre-Budget Report Review

A new tax rate of 10% for income derived from patients s to be introduced, compared to the current corporation tax rte of 28%. The details reveal that the new regime is set to apply to patents granted after April 2013, i.e. in more than 3 years time, with the legislation only to be included in the Finance Bill 2011, following consultation on the design of the scheme. Whilst this measure may appear to be aimed far into the future, the development of patented products can take time and the intention is clearly to encourage future R&D in the UK.

If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com

Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Avoid Expensive Mistakes, Keep On Top of New and Changing Regulations for Free.

As you know this website is a great resource for keeping up to date with developments and regulations, why not get our FREE monthly regulatory and market round up. You can un-subscribe at any time and we do not share your details with anybody.

Turn your Business Into an Investor Magnet

How to Write a Business Plan – Free E-Course

Get the secrets that turns your project into an investment magnet, 100% of our clients raise the finance they need to take their projects to the next stage, we will share these secrets with you. – Sign up for Free

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

i4i Funding Streams 3a (FPD3a) and 3b (FPD3b)

The NIHR’s Invention for Innovation (i4i) programme would like to invite submissions of applications to funding streams 3a and 3b (FPD3a and FPD3b).

Stream 3a applications must include collaboration between at least one industry and one research (academic or clinical) partner aiming to determine the commercial viability of a proposed device or technology, with the development of a robust route to market and a strong, appropriate consortia serving as key deliverables.  Primarily expected to be the first stage of a full collaborative applied research project, total project costs can be no more than £100K in total, of which 75% funding is available.

Stream 3b applications should build on the results of a completed assessment of feasibility and must also have collaboration between at least one industry and one research partner (academic or clinical). This will provide further evidence of the capability to deliver improved healthcare outcomes and commercial opportunity, delivering an advanced prototype along with plans for commercial and intellectual property exploitation. Lasting no longer than 3 years, successful projects will be funded to a maximum of 50% of the total project costs, with £100K-£300K per year in funding available.

All applications must show innovation and must have relevance, impact and potential to contribute to future health gain for patients and the general population.  This programme is open to research providers in the academic, NHS communities and industry across the UK.

For further information on eligibility and to submit an application please visit http://www.nihr-ccf.org.uk/site/programmes/i4i/ or email any questions that you may have to i4i.enquiries@quotec.co.uk.

Applications must be submitted via the NIHR CCF website no later than 5.00pm on Friday 29^th January 2010. Applicants will be notified of the outcome of their application by late March 2010.

If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com

Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Free Regulatory Watch Service

As you know this website is a great resource for keeping up to date with developments and regulations, why not get our FREE monthly regulatory and market round up. You can un-subscribe at any time and we do not share your details with anybody.

Turn your Business Into an Investor Magnet

How to Write a Business Plan – Free E-Course

Get the secrets that turns your project into an investment magnet, 100% of our clients raise the finance they need to take their projects to the next stage, we will share these secrets with you. – Sign up for Free

“Please note that the pages on this website are designed to provide you with general information only. We make no warranties, representations or undertakings about any of its content. This includes the completeness, accuracy and fitness for any particular purpose, or the content of any third party site referred to or accessed through it. You are personally responsible for ensuring that the information is correct and we will not be held liable or accountable for any mistakes that occur.”

Short Term Project Funding is designed to support small research projects to explore the feasibility of innovative new products and processes. In the first stage, funds of up to £3,000 are available to support collaborative projects between METRC’s academic members and industry partners. The funding can be used flexibly at the METRC academic  institutions on a range of activities such as project consumables, paying for researchers or some limited consultancy work. For the most successful projects, funding can be extended into a second stage worth up to an additional £7,000 providing there is a matching contribution from an industrial partner.

he call will open on 16th October 2009 and funding will be available on a first-come first-served basis. We will be accepting applications for stage 2 funding from 1st January 2010 and there is funding available to support up to 10 stage 2 projects. We expect that a second tranche of Short Term Project Funding will be made available during 2010.

The Contacts Are:

Richard France – r.m.france@sheffield.ac.uk, 0114 222 9563
Simon Butler – simon.butler@sheffield.ac.uk, 0114 222 9450
Sam Whitehouse – S.P.Whitehouse@sheffield.ac.uk, 0114 222 9493

If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com

Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.

Turn your Business Into an Investor Magnet

How to Write a Business Plan – Free E-Course

Get the secrets that turns your project into an investment magnet, 100% of our clients raise the finance they need to take their projects to the next stage, we will share these secrets with you. – Sign up for Free

Grow your Expertise for Free

As you know this website is a great resource for keeping up to date with developments and regulations, why not get our FREE monthly regulatory and market round up. You can un-subscribe at any time and we do not share your details with anybody.